Stacy Loeb1, Dawn Walter2, Caitlin Curnyn2, Heather T Gold2, Herbert Lepor3, Danil V Makarov4. 1. Department of Urology, New York University, New York, New York; Population Health, New York University, New York, New York; Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York. Electronic address: stacyloeb@gmail.com. 2. Population Health, New York University, New York, New York. 3. Department of Urology, New York University, New York, New York. 4. Department of Urology, New York University, New York, New York; Population Health, New York University, New York, New York; Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York.
Abstract
PURPOSE: While major prostate cancer active surveillance programs recommend repeat testing such as prostate specific antigen and prostate biopsy, to our knowledge compliance with such testing is unknown. We determined whether men in the community receive the same intensity of active surveillance testing as in prospective active surveillance protocols. MATERIALS AND METHODS: We performed a retrospective cohort study of men 66 years old or older in the SEER (Surveillance, Epidemiology and End Results)-Medicare database. These men were diagnosed with prostate cancer from 2001 to 2009, did not receive curative therapy in the year after diagnosis and underwent 1 or more post-diagnosis prostate biopsies. We used multivariable adjusted Poisson regression to determine the association of the frequency of active surveillance testing with patient demographics and clinical features. In 1,349 men with 5 years of followup we determined the proportion who underwent testing as intense as that recommended by the Sunnybrook Health Sciences Centre and PRIAS (Prostate Cancer Research International Active Surveillance) programs, including 14 or more PSA tests and 2 or more biopsies, and The Johns Hopkins program, including 10 or more prostate specific antigen tests and 4 or more biopsies. RESULTS: Among 5,192 patients undergoing active surveillance greater than 80% had 1 or more prostate specific antigen tests per year but fewer than 13% underwent biopsy beyond the first 2 years. Magnetic resonance imaging was rarely done during the study period. On multivariable analysis recent diagnosis and higher income were associated with a higher frequency of surveillance biopsy while older age and greater comorbidity were associated with fewer biopsies. African American men underwent fewer prostate specific antigen tests but a similar number of biopsies. During 5 years of active surveillance only 11.1% and 5.0% of patients met the testing standards of the Sunnybrook/PRIAS and The Johns Hopkins programs, respectively. CONCLUSIONS: In the community few elderly men receive the intensity of active surveillance testing recommended in major prospective active surveillance programs.
PURPOSE: While major prostate cancer active surveillance programs recommend repeat testing such as prostate specific antigen and prostate biopsy, to our knowledge compliance with such testing is unknown. We determined whether men in the community receive the same intensity of active surveillance testing as in prospective active surveillance protocols. MATERIALS AND METHODS: We performed a retrospective cohort study of men 66 years old or older in the SEER (Surveillance, Epidemiology and End Results)-Medicare database. These men were diagnosed with prostate cancer from 2001 to 2009, did not receive curative therapy in the year after diagnosis and underwent 1 or more post-diagnosis prostate biopsies. We used multivariable adjusted Poisson regression to determine the association of the frequency of active surveillance testing with patient demographics and clinical features. In 1,349 men with 5 years of followup we determined the proportion who underwent testing as intense as that recommended by the Sunnybrook Health Sciences Centre and PRIAS (Prostate Cancer Research International Active Surveillance) programs, including 14 or more PSA tests and 2 or more biopsies, and The Johns Hopkins program, including 10 or more prostate specific antigen tests and 4 or more biopsies. RESULTS: Among 5,192 patients undergoing active surveillance greater than 80% had 1 or more prostate specific antigen tests per year but fewer than 13% underwent biopsy beyond the first 2 years. Magnetic resonance imaging was rarely done during the study period. On multivariable analysis recent diagnosis and higher income were associated with a higher frequency of surveillance biopsy while older age and greater comorbidity were associated with fewer biopsies. African American men underwent fewer prostate specific antigen tests but a similar number of biopsies. During 5 years of active surveillance only 11.1% and 5.0% of patients met the testing standards of the Sunnybrook/PRIAS and The Johns Hopkins programs, respectively. CONCLUSIONS: In the community few elderly men receive the intensity of active surveillance testing recommended in major prospective active surveillance programs.
Authors: Jamie Ritchey; E Greer Gay; Benjamin A Spencer; David C Miller; Lauren P Wallner; Andrew K Stewart; Rodney L Dunn; Mark S Litwin; John T Wei Journal: J Urol Date: 2012-07-19 Impact factor: 7.450
Authors: Eugene K Lee; Janet Baack; Heidi Penn; Cecil T Bromfield; David A Duchene; J Brantley Thrasher; Jeffrey M Holzbeierlein Journal: Can J Urol Date: 2010-12 Impact factor: 1.344
Authors: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Karim Chamie; Stephen B Williams; Dawn L Hershman; Jason D Wright; Paul L Nguyen; Jim C Hu Journal: Cancer Date: 2015-08-26 Impact factor: 6.860
Authors: Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag Journal: Ann Epidemiol Date: 2007-05-25 Impact factor: 3.797
Authors: Satoshi Anai; Kogenta Nakamura; Myron N Chang; John Pendleton; Saif Yacoub; Charles J Rosser Journal: J Health Care Poor Underserved Date: 2008-02
Authors: Ola Bratt; Stefan Carlsson; Erik Holmberg; Lars Holmberg; Eva Johansson; Andreas Josefsson; Annika Nilsson; Maria Nyberg; David Robinsson; Jonas Sandberg; Dag Sandblom; Pär Stattin Journal: Scand J Urol Date: 2013-07-24 Impact factor: 1.612
Authors: J Curtis Nickel; Michael A Gorin; Partin Alan W; Stacy Loeb; Shapiro Ellen; Michael B Chancellor; Dean G Assimos; Michael K Brawer; Benjamin M Brucker Journal: Rev Urol Date: 2016
Authors: Liam C Macleod; Jonathan G Yabes; Mina M Fam; Jathin Bandari; Michelle Yu; Avinash Maganty; Alessandro Furlan; Christopher P Filson; Benjamin J Davies; Bruce L Jacobs Journal: Eur Urol Focus Date: 2019-04-25
Authors: Archana Radhakrishnan; Lauren P Wallner; Ted A Skolarus; Vahakn B Shahinian; Paul H Abrahamse; Michael D Fetters; Sarah T Hawley Journal: Urol Pract Date: 2021-04-22
Authors: Amy N Luckenbaugh; Gregory B Auffenberg; Scott R Hawken; Apoorv Dhir; Susan Linsell; Sanjeev Kaul; David C Miller Journal: J Urol Date: 2016-09-20 Impact factor: 7.450
Authors: Bashir Al Hussein Al Awamlh; Neal Patel; Xiaoyue Ma; Adam Calaway; Lee Ponsky; Jim C Hu; Jonathan E Shoag Journal: Front Oncol Date: 2021-05-19 Impact factor: 6.244
Authors: Lars Björnebo; Henrik Olsson; Tobias Nordström; Fredrik Jäderling; Henrik Grönberg; Martin Eklund; Anna Lantz Journal: World J Urol Date: 2020-07-30 Impact factor: 4.226
Authors: Richard M Hoffman; Sarah L Mott; Bradley D McDowell; Sonia T Anand; Kenneth G Nepple Journal: Prostate Cancer Prostatic Dis Date: 2021-06-09 Impact factor: 5.455